CA
IMCR icon

Clearstead Advisors’s Immunocore IMCR Stock Holding History

Clearstead Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-348
Closed -$10.3K – 2807
2025
Q1 		$10.3K Hold
348
– – ﹤0.01% 1597
2024
Q4 		$10.3K Hold
348
– – ﹤0.01% 1562
2024
Q3 		$10.8K Hold
348
– – ﹤0.01% 1567
2024
Q2 		$11.8K Buy
+348
New +$17.7K ﹤0.01% 1517

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Clearstead Advisors's IMCR Position: Q2 2025 in Review

Clearstead Advisors sold out of Immunocore (IMCR) in Q2 2025, closing a stake of 348 shares — an estimated $10.3K sold.

Clearstead Advisors first reported a position in IMCR in Q2 2024 and held it in 4 quarters. The position peaked at $11.8K in Q2 2024. 133 funds tracked by Wall St. Rank hold IMCR as of Q2 2025.

  • Clearstead Advisors reported no remaining Immunocore position as of Q2 2025 after selling out during the quarter.
  • Clearstead Advisors sold 348 Immunocore shares in Q2 2025, an estimated $10.3K.
  • Clearstead Advisors first reported a position in Immunocore in Q2 2024 and held it in 4 quarters.
  • Clearstead Advisors's Immunocore position peaked at $11.8K in Q2 2024.
  • 133 funds tracked by Wall St. Rank held Immunocore as of Q2 2025.

Based on Clearstead Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.